|
1
|
Khor B, Gardet A and Xavier RJ: Genetics
and pathogenesis of inflammatory bowel disease. Nature.
474:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sartor RB: Mechanisms of disease:
Pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin
Pract Gastroenterol Hepatol. 3:390–407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lennard-Jones JE, Morson BC, Ritchie JK
and Williams CB: Cancer surveillance in ulcerative colitis.
Experience over 15 years. Lancet. 2:149–152. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanchez-Munoz F, Dominguez-Lopez A and
Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel
disease. World J Gastroenterol. 14:4280–4288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gioannini TL and Weiss JP: Regulation of
interactions of Gram-negative bacterial endotoxins with mammalian
cells. Immunol Res. 39:249–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krappmann D, Wegener E, Sunami Y, Esen M,
Thiel A, Mordmuller B and Scheidereit C: The IkappaB kinase complex
and NF-kappaB act as master regulators of
lipopolysaccharide-induced gene expression and control subordinate
activation of AP-1. Mol Cell Biol. 24:6488–6500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kueanjinda P, Roytrakul S and Palaga T: A
novel role of numb as a regulator of pro-inflammatory cytokine
production in macrophages in response to toll-like receptor 4 (vol
5, 12784, 2015). Sci Rep. 5:127842015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tong ZM, Wu XL, Ovcharenko D, Zhu JX, Chen
CS and Kehrer JP: Neutrophil gelatinase-associated lipocalin as a
survival factor. Biochem J. 391:441–448. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kjeldsen L, Johnsen AH, Sengelov H and
Borregaard N: Isolation and primary structure of ngal, a novel
protein associated with human neutrophil gelatinase. J Biol Chem.
268:10425–10432. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akerstrom B, Flower DR and Salier JP:
Lipocalins: Unity in diversity. Biochim Biophys Acta. 1482:1–8.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen F, Hu Z, Goswami J and Gaffen SL:
Identification of common transcriptional regulatory elements in
interleukin-17 target genes. J Biol Chem. 281:24138–24148. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lawrence T and Natoli G: Transcriptional
regulation of macrophage polarization: Enabling diversity with
identity. Nat Rev Immunol. 11:750–761. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao P and Stephens JM: STAT1, NF-κB and
ERKs play a role in the induction of lipocalin-2 expression in
adipocytes. Mol Metab. 2:161–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo H, Jin D and Chen X: Lipocalin 2 is a
regulator of macrophage polarization and NF-κB/STAT3 pathway
activation. Mol Endocrinol. 28:1616–1628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Warszawska JM, Gawish R, Sharif O, Sigel
S, Doninger B, Lakovits K, Mesteri I, Nairz M, Boon L, Spiel A, et
al: Lipocalin 2 deactivates macrophages and worsens pneumococcal
pneumonia outcomes. J Clin Invest. 123:3363–3372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Borkham-Kamphorst E, de Leur EV,
Zimmermann HW, Karlmark KR, Tihaa L, Haas U, Tacke F, Berger T, Mak
TW and Weiskirchen R: Protective effects of lipocalin-2 (LCN2) in
acute liver injury suggest a novel function in liver homeostasis.
Biochim Biophys Acta. 1832:660–673. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Srinivasan G, Aitken JD, Zhang BY,
Carvalho FA, Chassaing B, Shashidharamurthy R, Borregaard N, Jones
DP, Gewirtz AT and Vijay-Kumar M: Lipocalin 2 deficiency
dysregulates iron homeostasis and exacerbates endotoxin-induced
sepsis. J Immunol. 189:1911–1919. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang YY, Foncea R, Deis JA, Guo H,
Bernlohr DA and Chen XL: Lipocalin 2 expression and secretion is
highly regulated by metabolic stress, cytokines, and nutrients in
adipocytes. Plos One. 9:e969972014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chassaing B, Srinivasan G, Delgado MA,
Young AN, Gewirtz AT and Vijay-Kumar M: Fecal lipocalin 2, a
sensitive and broadly dynamic non-invasive biomarker for intestinal
inflammation. Plos One. 7:e443282012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nielsen OH, Gionchetti P, Ainsworth M,
Vainer B, Campieri M, Borregaard N and Kjeldsen L: Rectal dialysate
and fecal concentrations of neutrophil gelatinase-associated
lipocalin, interleukin-8, and tumor necrosis factor-alpha in
ulcerative colitis. Am J Gastroenterol. 94:2923–2928. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim SL, Shin MW, Seo SY and Kim SW:
Lipocalin 2 potentially contributes to tumorigenesis from colitis
via IL-6/STAT3/NF-κB signaling pathway. Biosci Rep.
42:BSR202124182022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lawrence T: The nuclear factor NF-kappaB
pathway in inflammation. Cold Spring Harb Perspect Biol.
1:a0016512009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O'Dea E and Hoffmann A: NF-κB signaling.
Wiley Interdiscip Rev Syst Biol Med. 1:107–115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sharif O, Bolshakov VN, Raines S, Newham P
and Perkins ND: Transcriptional profiling of the LPS induced
NF-kappaB response in macrophages. BMC Immunol. 8:12007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allen IC, TeKippe EM, Woodford RM, Uronis
JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JPY: The
NLRP3 inflammasome functions as a negative regulator of
tumorigenesis during colitis-associated cancer. J Exp Med.
207:1045–1056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu T, Zhang L, Joo D and Sun SC: NF-κB
signaling in inflammation. Signal Transduct Target Ther.
2:170232017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Swanson KV, Deng M and Ting JP: The NLRP3
inflammasome: Molecular activation and regulation to therapeutics.
Nat Rev Immunol. 19:477–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han X, Ding S, Jiang H and Liu G: Roles of
macrophages in the development and treatment of gut inflammation.
Front Cell Dev Biol. 9:6254232021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oikonomou KA, Kapsoritakis AN, Theodoridou
C, Karangelis D, Germenis A, Stefanidis I and Potamianos SP:
Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory
bowel disease: Association with pathophysiology of inflammation,
established markers, and disease activity. J Gastroenterol.
47:519–530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ostvik AE, Granlund AV, Torp SH, Flatberg
A, Beisvag V, Waldum HL, Flo TH, Espevik T, Damås JK and Sandvik
AK: Expression of toll-like receptor-3 is enhanced in active
inflammatory bowel disease and mediates the excessive release of
lipocalin 2. Clin Exp Immunol. 173:502–511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baumgart DC and Carding SR: Inflammatory
bowel disease: Cause and immunobiology. Lancet. 369:1627–1640.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Geremia A, Biancheri P, Allan P, Corazza
GR and Di Sabatino A: Innate and adaptive immunity in inflammatory
bowel disease. Autoimmun Rev. 13:3–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Geremia A and Arancibia-Carcamo CV: Innate
lymphoid cells in intestinal inflammation. Front Immunol.
8:12962017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
West MA, Seatter SC, Bellingham J and
Clair L: Mechanisms of reprogrammed macrophage endotoxin signal
transduction after lipopolysaccharide pretreatment. Surgery.
118:220–228. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo H, Jin D and Chen X: Lipocalin 2 is a
regulator of macrophage polarization and NF-κB/STAT3 pathway
activation. Mol Endocrinol. 28:1616–1628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Du H, Liang L, Li J, Xiong Q, Yu X and Yu
H: Lipocalin-2 Alleviates LPS-induced inflammation through
alteration of macrophage properties. J Inflamm Res. 14:4189–4203.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Q and Verma IM: NF-kappaB regulation in
the immune system. Nat Rev Immunol. 2:725–734. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rogler G, Brand K, Vogl D, Page S,
Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Schölmerich J and
Gross V: Nuclear factor kappaB is activated in macrophages and
epithelial cells of inflamed intestinal mucosa. Gastroenterology.
115:357–369. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Z, Liu N and Chen X, Zhang F, Kong
T, Tang X, Yang Q, Chen W, Xiong X and Chen X: UCHL1 regulates
inflammation via MAPK and NF-κB pathways in LPS-activated
macrophages. Cell Biol Int. 45:2107–2117. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nam Y, Kim JH, Seo M, Kim JH, Jin M, Jeon
S, Seo JW, Lee WH, Bing SJ, Jee Y, et al: Lipocalin-2 protein
deficiency ameliorates experimental autoimmune encephalomyelitis:
The pathogenic role of lipocalin-2 in the central nervous system
and peripheral lymphoid tissues. J Biol Chem. 289:16773–16789.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bachman MA, Miller VL and Weiser JN:
Mucosal lipocalin 2 has pro-inflammatory and iron-sequestering
effects in response to bacterial enterobactin. PLoS Pathog.
5:e10006222009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Coll RC, Robertson AA, Chae JJ, Higgins
SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG,
Stutz AJ, et al: A small-molecule inhibitor of the NLRP3
inflammasome for the treatment of inflammatory diseases. Nat Med.
21:248–255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Abderrazak A, Syrovets T, Couchie D, El
Hadri K, Friguet B, Simmet T and Rouis M: NLRP3 inflammasome: From
a danger signal sensor to a regulatory node of oxidative stress and
inflammatory diseases. Redox Biol. 4:296–307. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sutterwala FS, Haasken S and Cassel SL:
Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci.
1319:82–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Song E, Jahng JW, Chong LP, Sung HK, Han
M, Luo C, Wu D, Boo S, Hinz B, Cooper MA, et al: Lipocalin-2
induces NLRP3 inflammasome activation via HMGB1 induced TLR4
signaling in heart tissue of mice under pressure overload
challenge. Am J Transl Res. 9:2723–2735. 2017.PubMed/NCBI
|
|
46
|
Zaki MH, Lamkanfi M and Kanneganti TD: The
Nlrp3 inflammasome: Contributions to intestinal homeostasis. Trends
Immunol. 32:171–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Haneklaus M, Gerlic M, O'Neill LA and
Masters SL: MiR-223: Infection, inflammation and cancer. J Intern
Med. 274:215–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mariathasan S and Monack DM: Inflammasome
adaptors and sensors: Intracellular regulators of infection and
inflammation. Nat Rev Immunol. 7:31–40. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Martinon F, Burns K and Tschopp J: The
inflammasome: A molecular platform triggering activation of
inflammatory caspases and processing of proIL-beta. Mol Cell.
10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Reinecker HC, Steffen M, Witthoeft T,
Pflueger I, Schreiber S, MacDermott RP and Raedler A: Enhanced
secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by
isolated lamina propria mononuclear cells from patients with
ulcerative colitis and Crohn's disease. Clin Exp Immunol.
94:174–181. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Klampfer L: Cytokines, inflammation and
colon cancer. Curr Cancer Drug Targets. 11:451–464. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cowland JB, Sorensen OE, Sehested M and
Borregaard N: Neutrophil gelatinase-associated lipocalin is
up-regulated in human epithelial cells by IL-1 beta, but not by
TNF-alpha. J Immunol. 171:6630–6639. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cowland JB, Muta T and Borregaard N:
IL-1beta-specific up-regulation of neutrophil gelatinase-associated
lipocalin is controlled by IkappaB-zeta. J Immunol. 176:5559–5566.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Canna SW, Girard C, Malle L, de Jesus A,
Romberg N, Kelsen J, Surrey LF, Russo P, Sleight A, Schiffrin E, et
al: Life-threatening NLRC4-associated hyperinflammation
successfully treated with IL-18 inhibition. J Allergy Clin Immunol.
139:1698–16701. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Garlanda C, Dinarello CA and Mantovani A:
The interleukin-1 family: Back to the future. Immunity.
39:1003–1018. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sims JE and Smith DE: The IL-1 family:
Regulators of immunity. Nat Rev Immunol. 10:89–102. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhu Q and Kanneganti TD: Cutting edge:
Distinct regulatory mechanisms control proinflammatory cytokines
IL-18 and IL-1β. J Immunol. 198:4210–4215. 2017. View Article : Google Scholar : PubMed/NCBI
|
